<p><h1>Enasidenib Market with the goal of estimating the market size and future growth potential of various market segments based on component, applications, end user and region</h1></p><p><strong>Enasidenib Market Analysis and Latest Trends</strong></p>
<p><p>Enasidenib is a medication used in the treatment of acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. It is an oral inhibitor of the mutated IDH2 protein, which disrupts the production of 2-hydroxyglutarate, a metabolite that promotes the proliferation of leukemic cells. By inhibiting the IDH2 mutation, Enasidenib helps to restore normal cell differentiation and inhibit the growth of AML cells.</p><p>The global Enasidenib market has been experiencing significant growth due to the rising incidence of AML and the increasing demand for effective treatments. The market is driven by factors such as the growing geriatric population, which is more susceptible to AML, and the ongoing research and development activities in the field of oncology.</p><p>According to market growth analysis and the latest trends, the Enasidenib market is expected to witness a CAGR of 7% during the forecast period. The market is expected to be driven by factors such as increasing awareness about the available treatment options for AML, advancements in precision medicine, and the development of novel therapies. Additionally, the increasing healthcare expenditure in developing economies and the growing focus on personalized medicine are also expected to contribute to market growth.</p><p>The Enasidenib market is characterized by the presence of several key players. These players are actively involved in developing innovative therapies and expanding their product portfolios through strategic collaborations and partnerships. Furthermore, the market is witnessing an increasing number of clinical trials and research studies, which are expected to fuel the growth of the Enasidenib market in the coming years.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1709310">https://www.reliableresearchreports.com/enquiry/request-sample/1709310</a></p>
<p>&nbsp;</p>
<p><strong>Enasidenib Major Market Players</strong></p>
<p><p>Enasidenib, marketed under the brand name Idhifa, is an oral inhibitor of isocitrate dehydrogenase 2 (IDH2), developed by Celgene Corporation. It is used for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. With a global market value forecasted to reach $256 million by 2026, the Enasidenib market is highly competitive, with several key players vying for market share.</p><p>Celgene Corporation, a well-established multinational biopharmaceutical company, has made significant strides in the Enasidenib market. The company has been able to drive market growth by developing innovative treatments and expanding its global reach. Celgene has a strong pipeline and is continuously investing in research and development to bring forth more treatment options for AML patients. The company's commitment to fulfilling unmet medical needs and improving patient outcomes has resulted in its consistent growth in the Enasidenib market.</p><p>In terms of future growth, Celgene Corporation is expected to maintain its market dominance by leveraging its extensive expertise in oncology and strategic collaborations. The company recently announced a merger with Bristol-Myers Squibb Company, which will further strengthen its presence in the AML market. This merger will combine Celgene's IDH2 inhibitors with Bristol-Myers Squibb's immune-oncology portfolio, creating a powerful combination for treating AML patients.</p><p>While the exact sales revenue figures for Celgene Corporation's Enasidenib are not provided, it is worth mentioning that the company's total net product sales for 2018 amounted to approximately $15.2 billion. This figure includes revenue from various drugs across multiple therapeutic areas, including oncology.</p><p>Apart from Celgene Corporation, other key players in the Enasidenib market include Agios Pharmaceuticals, Inc., which developed Enasidenib in collaboration with Celgene, and publicly traded companies like Servier Pharmaceuticals and Takeda Pharmaceutical Company Limited. These players have also made significant investments in research and development to expand their product portfolios and capture a larger market share.</p><p>In conclusion, Celgene Corporation, along with other major players, is driving the growth of the Enasidenib market through its focus on innovation, extensive research, and strategic collaborations. With its strong market presence and commitment to improving patient outcomes, Celgene is well-positioned to capitalize on the growing demand for Enasidenib and maintain its leadership in the market.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Enasidenib Manufacturers?</strong></p>
<p><p>The Enasidenib market has witnessed steady growth over the past few years and is expected to continue its upward trajectory in the near future. Key factors driving the market include the rising incidence of acute myeloid leukemia (AML) and the growing adoption of targeted therapies. Furthermore, the increasing demand for personalized medicine and advancements in genomic profiling are fueling the market's growth. With several ongoing clinical trials and the potential for label expansions, Enasidenib market is projected to witness substantial growth. Additionally, collaborations between pharmaceutical companies and research institutions are expected to drive innovation and further boost market growth in the coming years.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1709310">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1709310</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Enasidenib Market Analysis by types is segmented into:</strong></p>
<p><ul><li>50mg</li><li>100mg</li></ul></p>
<p><p>Enasidenib is a pharmaceutical drug available in two market types: 50mg and 100mg. These market types refer to the different strengths or dosages of the drug that are offered to patients. The 50mg market provides a lower dosage option for individuals who require a milder treatment, while the 100mg market caters to patients who need a higher dosage for a more potent therapeutic effect. These market types allow healthcare providers to prescribe the appropriate strength of Enasidenib based on the specific needs and conditions of their patients.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliableresearchreports.com/purchase/1709310">https://www.reliableresearchreports.com/purchase/1709310</a></p>
<p>&nbsp;</p>
<p><strong>The Enasidenib Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Hospital</li><li>Pharmacy</li></ul></p>
<p><p>Enasidenib, an orally administered drug, has demonstrated promising results in the treatment of certain types of cancer, specifically acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation. In the hospital market, enasidenib is positioned as an effective targeted therapy that can potentially improve patient outcomes. In the pharmacy market, enasidenib is available for prescription sales and can be dispensed to patients in need. With its recognized therapeutic potential, enasidenib has gained traction in both markets as an innovative treatment option for eligible patients.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Enasidenib Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The Enasidenib market is expected to exhibit significant growth in several regions including North America (NA), Asia-Pacific (APAC), Europe, the United States of America (USA), and China. The market is projected to grow at a steady pace in these regions due to the increasing prevalence of acute myeloid leukemia (AML) and the rising demand for targeted therapies. Among these regions, North America is anticipated to dominate the market, holding the largest market share of approximately 40%. Europe is expected to closely follow with a market share of around 30%, while APAC, USA, and China are likely to account for approximately 15%, 10%, and 5% of the market share respectively.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliableresearchreports.com/purchase/1709310">https://www.reliableresearchreports.com/purchase/1709310</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliableresearchreports.com/enquiry/request-sample/1709310">https://www.reliableresearchreports.com/enquiry/request-sample/1709310</a></p>
<p><strong></strong></p>
<p>Check more reports on https://www.reliableresearchreports.com/</p>